Roivant Sciences (ROIV) director discloses indirect sales of common shares

Rhea-AI Filing Summary

Roivant Sciences Ltd. director Dan Gold reported multiple sales of the company’s Common Shares made indirectly through QVT Financial Investment Cayman Ltd. On 12/16/2025, QVT FIC sold 275,000 Common Shares at a price of $22.93 per share and 642,282 Common Shares at $23.08 per share. On 12/17/2025, QVT FIC sold additional blocks of 432,718, 155,076, and 189,538 Common Shares at prices of $23.05, $23.02, and $23.17 per share, respectively.

Following these transactions, QVT FIC is reported to beneficially own 16,353,113 Roivant Common Shares, which are reported as indirectly owned by Gold through his role as one of three directors of QVT FIC. Gold disclaims beneficial ownership of these securities beyond his pecuniary interest.

Insider Trade Summary

Net Seller: 1,694,614 shares ($39,065,213)

Net Sell 5 txns

Insider Gold Daniel Allen

Role Director

Sold 1,694,614 shs ($39.07M)

Type	Security	Shares	Price	Value
Sale	Common Shares	432,718	$23.05	$9.97M
Sale	Common Shares	155,076	$23.02	$3.57M
Sale	Common Shares	189,538	$23.17	$4.39M
Sale	Common Shares	275,000	$22.93	$6.31M
Sale	Common Shares	642,282	$23.08	$14.82M

Holdings After Transaction: Common Shares — 16,697,727 shares (Indirect, Held by QVT Financial Investment Cayman Ltd.)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gold Daniel Allen

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON X0 SW1H 0DB

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	12/16/2025		S		275,000	D	$22.93	17,772,727	I(1)	Held by QVT Financial Investment Cayman Ltd.
Common Shares	12/16/2025		S		642,282	D	$23.08	17,130,445	I(1)	Held by QVT Financial Investment Cayman Ltd.
Common Shares	12/17/2025		S		432,718	D	$23.05	16,697,727	I(1)	Held by QVT Financial Investment Cayman Ltd.
Common Shares	12/17/2025		S		155,076	D	$23.02	16,542,651	I(1)	Held by QVT Financial Investment Cayman Ltd.
Common Shares	12/17/2025		S		189,538	D	$23.17	16,353,113	I(1)	Held by QVT Financial Investment Cayman Ltd.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person is one of three directors of QVT Financial Investment Cayman Ltd. ("QVT FIC"), sharing voting and investment control over the Common Shares held directly by QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.

	/s/ Dan Gold	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Roivant Sciences (ROIV) disclose in this Form 4?

The filing reports that director Dan Gold, through QVT Financial Investment Cayman Ltd., sold multiple blocks of Roivant Sciences Ltd. Common Shares on 12/16/2025 and 12/17/2025 at prices around $23 per share.

How many Roivant Sciences (ROIV) shares were sold in the reported transactions?

QVT Financial Investment Cayman Ltd. sold 275,000 and 642,282 Common Shares on 12/16/2025, and 432,718, 155,076, and 189,538 Common Shares on 12/17/2025.

At what prices were the Roivant Sciences (ROIV) shares sold?

The Common Shares were sold at prices of $22.93, $23.08, $23.05, $23.02, and $23.17 per share, depending on the specific transaction date and block size.

How many Roivant Sciences (ROIV) shares does the reporting person beneficially own after these sales?

After the reported transactions, the filing states that 16,353,113 Roivant Common Shares are beneficially owned indirectly through QVT Financial Investment Cayman Ltd.

What is Dan Gold’s relationship to Roivant Sciences (ROIV) and QVT Financial Investment Cayman Ltd.?

Dan Gold is a director of Roivant Sciences Ltd. and one of three directors of QVT Financial Investment Cayman Ltd., sharing voting and investment control over the Common Shares held by QVT FIC.

Does the reporting person claim full beneficial ownership of all the Roivant (ROIV) shares held by QVT FIC?

No. The filing states that the reporting person disclaims beneficial ownership of the securities held by QVT FIC except to the extent of his pecuniary interest, and that including these shares in the report is not an admission of full beneficial ownership.